Clinical Trials
Sanofi-aventis Reports Top-line Results from Phase III Study with BSI-201 in Metastatic Triple-Negative Breast Cancer
Sanofi-aventis and its subsidiary, BiPar Sciences, announced that a randomized Phase III trial evaluating BSI-201 (iniparib*) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and...
Clinical Trials
Patients enrolled in EU Phase III Clinical Development Progam to evaluate ATX-101 for Reduction of Submental Fat
Bayer HealthCare’s dermatology business Intendis and KYTHERA Biopharmaceuticals, Inc. announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat). ...
Clinical Trials
VistaGen Therapeutics Announces Successful Completion of Initial Phase 1 Safety Study of AV-101
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company’s novel orally available prodrug candidate for treatment of neuropathic...
Clinical Trials
Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
Gilead Sciences, Inc.announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis...
Clinical Trials
Genentech Phase II study shows Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor
Genentech, a member of the Roche Group announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and Herceptin® (trastuzumab) plus chemotherapy (docetaxel) in women with early-stage, HER2-positive...
Clinical Trials
Novartis study shows drug Afinitor plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor...
Clinical Trials
Phase III study showed Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80% by Roche
Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease). Based on results of previous studies1 that showed no...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read